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Background: This study aimed to evaluate the behavior of non-muscle-invasive bladder cancer (NMIBC) in patients
submitted to transurethral bladder resection (TURB) comparing subjects in chronic therapy with aspirin, statins, or
both drugs to untreated ones.
Methods: This retrospective study was conducted on 574 patients diagnosed with NMIBC who underwent TURB
between March 2008 and April 2013. The study population was divided into two main groups: treated (aspirin
and/or statins) and untreated. The treated group was further divided into three therapeutic subgroups: Group A
(100 mg of aspirin, daily for at least two years); Group B (20 mg or more of statins, daily for at least two years);
and Group C (100 mg of aspirin and 20 mg of statins together). The mean follow-up of patients was 45.06 months.
Results: No significant differences were observed among the different groups at baseline. On multivariate analysis,
statin treatment, smokers and high stage disease (T1) achieved the level of independent risk factor for the occurrence
of a recurrence. When patients were stratified according to the different treatment; patients treated with statins
(Group B) presented an higher rate of failure (56/91 patients; 61.5%) when compared to Group A (42/98 patients;
42.9%), Group C (56/98; 57.1%) and (133/287 patients; 46.3%). This difference corresponds to a significant difference
in recurrence failure free survival (p = 0.01).
Conclusions: Our results suggest that long-term treatment with aspirin in patients with NMIBC might play a role on
reducing the risk of tumor recurrence. In contrast, in our investigation data from statins and combination treatment
groups showed increased recurrence rates. A long-term randomized prospective study could definitively assess the
possible role of this widely used drugs in NMIBC.
Keywords: Non muscle invasive bladder cancer, Aspirin, Statin, Transurethral bladder resection* Correspondence: antopast@hotmail.com
1Department of Medico-Surgical Sciences and Biotechnologies, Sapienza
University of Rome, Faculty of Pharmacy and Medicine, Urology Unit
ICOT, Via Franco Faggiana 1668, Latina 04100, Italy
2Uroresearch Association, non-profit research, Latina, Italy
Full list of author information is available at the end of the article
© 2015 Pastore et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Pastore et al. BMC Cancer  (2015) 15:120 Page 2 of 7Background
Urothelial bladder cancer (UBC) is common in Western
countries, where it is the fourth and ninth most
common cancer in men and women, respectively [1].
This frequency, coupled with the relapsing nature of
UBC, means that this disease poses an enormous
burden on health-care systems. Approximately 75%
of newly diagnosed UBCs are non-invasive, but they
have a high rate of recurrence and progression despite
local treatment. The other 25% are muscle-invasive and
require either radical surgery or radiotherapy, and have
poor outcomes despite systemic therapy [1].
The purpose of this retrospective study was to
compare the behavior of nonmuscle- invasive bladder
cancer (NMIBC) between patients who had undergone
transurethral bladder resection (TURB) in chronic treat-
ment with aspirin, statins, or a combination of these two
drugs and similarly operated patients who were not
treated with aspirin or statins. The present study
aimed to determine whether daily treatment with
these medications, widely used for the prevention of
cardiovascular disease, can affect the prognosis of UBC.
The main target in determining the chemopreventive
effect of aspirin and other non-steroidal anti-Inflammatory
drugs (NSAIDs) is the inhibition of cyclooxygenase (COX)
or prostaglandin-endoperoxide synthase, especially its
isoform 2, which is overexpressed in many tumor cell
lines, including bladder cancer (BC) [2-7]. Many studies
have shown that COX inhibitors have a preventive
effect and are able to induce remission of BC in animal
models [7,8].
An additional aim of our study was to analyze the
behavior of NMIBC in patients treated daily with statins
undergoing TURB. The primary effect of statins is the
reduction of low-density lipoproteins, an effect that is
associated with an anti-inflammatory action. The possible
role of statins in the processes of carcinogenesis and,
particularly, in UBC is still not completely defined [9-12].
We also focused our attention on patients treated with
both aspirin and statins. The effect of this therapeutic
combination on the progression and behavior of NMIBC
after TURB has not been studied previously. We
compared results obtained in this population with
results in the other treatment sub-populations and in
untreated patients.
Methods
This retrospective study evaluated information from 792
patients with NMIBC who underwent TURB between
March 2008 and April 2013. The study was performed in
accordance with the Ethical Principles for Medical Research
Involving Human Subjects (World Medical Association,
The Declaration of Helsinki Principles, 2000). This study
was approved by the local ethics committee of Hospital[ASL Lt/no. 1674/2013], and written informed consent was
obtained from all patients [or University].
The data were collected through a careful analysis of
the database archive of the Department of Urology.
Seventy-two patients were excluded because of lack of data
regarding smoking habits, 31 were excluded because of lack
of histopathological data, and 94 were not considered
because of lack of personal treatment data. Among the
remaining 595 patients, 21 women were excluded, for the
lack of some follow-up data, in order to obtain two study
groups that were statistically homogeneous and comparable.
In the remaining population of 574 patients, the
following parameters were considered: age, smoking,
and therapy, with particular attention to intake of aspirin
and/or statins (Table 1). None of the recruited patients
was previously submitted to TURB. A total of 287 patients
were in treatment with aspirin (100 mg daily for at least
2 years), or with statins (≥20 mg daily for at least 2 years),
or simultaneously with both drugs.
Smoking habits of the patients were categorized as
follows: current smokers (203), former smokers (189;
no smoking for at least 12 months), and non-smokers
(182; had smoked less than 100 cigarettes during their
lifetime). The following parameters for BC were considered:
number of resections, number of total lesions at the first
diagnosis, and histopathological findings in recurrent
tumors. All surgical specimens were staged (with re-
evaluation of those resected before 2009), according
to the TNM classification of the Union Internationale
Contre le Cancer (UICC), updated in 2009 [13]; tumor
grading was evaluated according to the 2004 World
Health Organization (WHO) classification for UBC [14].
Histopathological data were evaluated according to the
following criteria: the possible presence of concomitant
carcinoma in situ; architecture of tumor (papillary or ses-
sile, according to the characteristic predominant lesion);
possible infiltration of lymph-vascular space (defined
by the presence of tumor cells within the spaces
delimited by endothelial cells); and possible tumor
necrosis (the presence of coagulative necrosis in more
than 10% of the lesion).
No patient received neo-adjuvant therapy, adjuvant
systemic chemotherapy, or radiotherapy, but intravesical
adjuvant therapy was administered according to the tumor
staging and grading of each patient.
The study population was represented by two groups:
treated (287 patients treated with aspirin and/or statins)
and untreated (287 patients not treated with these
medications). The treated group was further divided
into the following subcategories: Group A, 98 patients
treated with aspirin only; Group B, 91 patients treated
with statins only; Group C, 98 patients treated with both
aspirin and statins. The patients’ average age was 62.2 years
(mean, 62.2 ± 4; range, 61.2 to 63.2).
Table 1 Demographic and operative data of the enrolled population
Total Untreated Treated p - value
Patients 574 287 287
Age, yr; Mean (IQR) 62,24 (61,2-63,2) 62,78 (61,9-63,2) 61,61 (61,2-62,6) 0,2281
No Smokers 158 77 81
Smokers 200 133 67 0,778
Former Smokers 216 77 139
Stage 0,513
pTa 284 153 131
Cis 17 8 9
pT1 273 126 147
Grade 0,253
Low Grade 206 119 87
High Grade 368 168 200
Intravesical therapy 0.07
BCG 290 134 156
MytomicinC 284 153 131
SUBGROUPS Group A Group B Group C p - value
Patients 98 91 98
Age, yr; Mean (IQR) 61,43 (61,2-62,8) 61,31 (61,2-62,4) 62,71 (61,9-63,3) 0,639
IQR = Interquartile Range Group: A = Cardioaspirin; B = Statins; C = Association.
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EAU guidelines [14], consisted of urinary cytology, upper
urinary tract ultrasound, or computed tomography urog-
raphy for the first year, and cystoscopy every three months;
the follow-up evaluation was performed every six months
from the second to the fifth year, then annually. During
every follow-up visit, patients’ therapy was reevaluated, with
particular attention to the use of aspirin and statins. The
mean follow-up duration was 45.06 months (range: 16–74
months). Recurrent disease was defined according to the
American Cancer Society as the return of cancer after
treatment and after a period of time during which the
cancer could be detected, and at the site where it began
(somewhere else in the bladder or at distant sites) [14].
Statistical analysis
Statistical analysis was performed using the S-PSS 12.0
software. Evaluation of data distribution showed a
non-normal distribution of the study data set. Differences
between groups of patients in medians for quantitative
variables and differences in distributions for categorical
variables were tested with the Kruskal Wallis one way
analysis of variance and chi-square test, respectively.
Using multiple logistic regression with the enter method,
the statistical significant variables as assessed in the
univariate analysis were entered and investigated to pre-
dict the success of the procedure. The logistic regression
analysis was carried out using data from patients for
whom complete data were available. Age, stage, smokingstatus, treatment were used as predictors of recurrence.
Patients were also stratified according to the type of treat-
ment: no treatment; aspirin (Group A); statin (Group B);
aspirin + statin (Group C).
Time to failure was analyzed using Kaplan-Meier
estimates. Survival times were measured in months
and were censored at the date of a patient with a
diagnosis of bladder cancer recurrence. An alpha value of
5% was considered as threshold for significance. Data are
presented as mean ± standard deviation (SD). Odds ratios
and 95% CI’s were calculated for the parameters in each
group using no treatment; no smokers or low stage (Ta) as
reference group.
Results
The patient groups were similar for all considered
parameters, with equal distribution of age among
treated and untreated patient (p = 0.2281) and between the
subgroups A, B, C (p values > 0.05). The other clinical data,
treatment, and smoking habit (p = 0.788), tumor grade
(p = 0.253), and stage (p = 0.513) were similar between
the groups.
The analysis of data showed that within the treated
group compared to the untreated group: Group B had
the greatest number of resections (mean = 2.462 ± 0.418,
p <0.0001); Group A had fewer procedures (mean = 1.585 ±
0.116) than did the entire population, particularly among
the untreated group (mean = 1.643 ± 0.248). Significantly,
Group C had fewer resections (mean = 2.143 ± 0.312,
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The number of recurrences in the treated subgroups was
as follows: Group A, 42%; Group B, 61%; and, Group C,
57% (Figure 1B).
Patients treated with statins only (Group B) had the
highest number of recurrences (mean = 1.46 ± 0.418),
followed by patients treated with both aspirin and statins
(Group C; mean = 1.14 ± 0.312), and the untreated group
(mean = 0.64 ± 0.25; p < 0.05). Group A, the aspirin group,
as already evidenced by the number of resections, had
fewer recurrences (mean = 0.59 ± 0.116) than did the
untreated group (p = 0.042) (Figure 1C).
The correlation between the number of total lesions
and the type of drug used was not statistically significant
(p = 0.10). Comparing the number of lesions in recurrence
relative to pharmacotherapy, the following results were
obtained: subgroup A (aspirin), mean = 1.14 ± 0.397,
p = 0.0242; subgroup B (statins), mean = 3.69 ± 0.827,
p = 0.0188; subgroup C (both drugs), mean = 2.57 ±
0.797, p = 0.021; and untreated, mean = 1.41 ± 0.465
(Figure1D).
On multivariate analysis (Table 2), age, statin treatment,
smokers and high stage disease (T1) achieved the level of
independent risk factor for the occurrence of a recurrence.
When patients were stratified according to the different
treatment; patients treated with statins (Group B) presented
an higher rate of failure (56/91 patients; 61.5%) when
compared to Group A (42/98 patients; 42.9%), Group CFigure 1 Results from different treatment groups (untreated, aspirin,
relapsed patients; C) number of recurrences; and D) number of lesion(56/98; 57.1%) and (133/287 patients; 46.3%). This differ-
ence corresponds to a significant difference in failure free
survival (p = 0.01) as visualized in Figure 2.
Discussion
The cause of bladder cancer is multifactorial, determined
by genetic and epigenetic alterations in addition to
the direct and indirect effects of multiple risk factors.
The results obtained in this study demonstrate that
aspirin and statins are able to modify the behavior of
urothelial NMIBC.
We found a statistical significance in terms of number
of bladder resections performed from 2008 to 2013 in
those patients treated with aspirin and/or statins com-
pared to those not treated with either drug group. Further
evidence is given by the greater number of patients with
relapse of tumor, defined as those who have required at
least a second TURB, as well as the mean number of
recurrences per patient, which was significantly greater in
the treated patients.
The higher number of lesions in recurrence represents
another important result in the treated group compared
to the untreated group. In this analysis, which did not
distinguish between different treatment subgroups, the
prognosis of NMIBC for treated patients was worse than
that for untreated patients. In a more detailed analysis,
patients treated with aspirin (Group A) received signifi-
cantly fewer resections than did the entire population,statins and association): A) number of resections; B) rate of
s in relapses.
Table 2 Odds ratios and 95% confidence interval (CI) for predicting recurrence among patients undergoing to TURB at
univariate and multivariate model
Univariate Multivariate
OR: 95% CI p OR: 95% CI; p
Age 0.881: 0.846-0.917 0.001 0.871: 0.833-0.911 0.001
No Smokers Reference Reference
Smokers 2.17: 1.411-3.337 0.001 3.202; 1.983-5.171 0.001
Former smokers 2.594: 1.694-3.974 0.001 2.191; 1.382-3.478 0.001
No Treatment Reference Reference 0.261
Aspirin 0.868: 0.547-1.379 0.550 0.749: 0.452-1.239
Statins 1.853: 1.144-3.1 0.012 1.886: 1.095-3.247 0.022
Aspirin and Statins 1.544: 0.972-2.452 0.66 1.394: 0.852-2.279 0.186
Stage 0.681: 1.208-2.332 0.002 1.915: 1.335- 2.746 0.001
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untreated group.
Group A (aspirin) also had fewer patients with recur-
rence, fewer recurrences, and fewer lesions in recurrence
than did patients in the other treated groups and in the
untreated group.
Similar to results reported for colon cancer [2], our
study of BC has shown that regular intake of aspirin
(at least 100 mg daily for a minimum of 2 years)
significantly reduces the number of resections, number of
patients with recurrence, total recurrences, and the
number of lesions in recurrence compared to similar
conditions in the entire population studied. LiteratureFigure 2 Recurrence free survival in patients who received no treatm
and statins (D).reports have documented that aspirin, as well as other
NSAIDs, inhibits cyclooxygenase, especially COX-2, and
is able to protect against the development of several
neoplastic diseases [2,15-17].
Veitonmäki, et al., reported that the risk of prostate
cancer is decreased in patients treated with acetylsalicylic
acid but not with other NSAIDs [18]. In the pathogenesis
of cancer, COX-2 appears to be involved in the signaling
pathways linked to cell proliferation, migration, apoptosis,
and tumor angiogenesis [15,19,20].
Selective inhibitors of COX-2, such as etoricoxib and
celecoxib, can slow cell growth and induce apoptosis in
tumor cell lines, such as BC, in both humans and animalent (A), treated with aspirin (B), with statins (C) or with aspirin
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treatment with selective COX-2 inhibitors is directly
related, unlike aspirin, to a significant increase in
cardiovascular risk, thereby excluding the possible pre-
ventive use of these drugs [15]. The evidence of COX-2
over expression in UBC cell lines [3-7], as well as in colon
carcinoma [24], is widely accepted.
Several population-based case-controlled studies have
reported conflicting results about aspirin intake and BC
[23-26]. The most representative study included 1514
patients in Southern California, USA, and reported a
lower risk for BC in patients treated with acetylsalicylic
acid [25]. These results were confirmed by two other
case-controlled trials conducted in New Hampshire,
USA, and Sweden [26,27]. In contrast, Daugherty, et al.,
conducted the largest prospective evaluation of NSAIDs
and BC risk, using three well-characterized cohort
studies on more than 500,000 patients; they concluded
that regular use of NSAIDs, but not aspirin, reduced the
risk of BC, particularly for nonsmokers [28]. Thus, we can
state that there is no agreement on the role of aspirin in
the biological behavior of UBC.
In our study, the daily intake of statins (20 mg or more,
daily for at least 2 years) was significantly correlated with
a higher number of resections (Group B) than occurred in
the other treated groups, and especially than in the
untreated group. In Group C (statins and aspirin), the
statistical difference was less, but remained significant, in
comparison to values for patients treated with statins only.
Therefore, it might be assumed that the protective role of
aspirin is reduced by the simultaneous intake of statins.
Regarding patients with recurrence, a higher rate was
observed in Group B than in the other treated subgroups
and in untreated patients. This result supports the
hypothesis that statins could negatively influence the
protective effect of aspirin, as observed in patients
treated with both medications. The number of recurrences
per patient was higher in statins than in the aspirin sub-
group and in the untreated subgroup. Once again, the pro-
tective effect of aspirin was strongly decreased in Group C,
where the combination of drugs seems to have led to a
greater number of recurrences per patient. Another signifi-
cant result observed in the statin group was that of a
greater number of lesions in the cases of recurrence, com-
pared to the number in the rest of the studied population,
and especially compared to that in Group A.
Statins represent a pharmacological class widely used
for primary and secondary prevention of cardiovascular
events. The role of statins in carcinogenesis is still
controversial depending on the type of tumor. In a study
conducted on 88,125 cases and 362,254 controls, long-
term intake of statins (longer than 4 years) was associated
with a significantly increased risk of development and
recurrence of bladder and lung cancer [11,12]. In prostaticcancer, statins were associated with a reduced risk of
clinical progression and mortality [29].
Few studies have analyzed the long-term effect of
statins on BC. A recent meta-analysis showed that
long-term statins use did not significantly affect the
risk of BC, with an estimate relative risk (RR) = 1.07,
and the authors highlighted a need for randomized
controlled trials to determine the role of statins in BC
[30]. Our results clearly showed an increased number
of recurrences and lesions and an increased number
of resections in patients treated with statins.
To the best of our knowledge, this is the first study
that investigated the effects of combined aspirin and
statin use on the behavior and progression of NMIBC.
The results of Group C have demonstrated a statistically
increased number of resections, rate of relapsing patients,
number of recurrences, and number of lesions in relapse
compared with those outcomes in the untreated group
and, especially, in aspirin Group (A). Our results suggest
that aspirin therapy has a protective role in BC but
that statin therapy alone and statin therapy coupled
with aspirin therapy do not.
The major limitations of our study are its retrospective
design, the lack of stratification by type of statin, and
the limited sample size. Further investigation about
categories of statins in BC treatment is needed to
determine the role of this drug more decisively. It is
important to note that in our investigation, we analyzed a
statistically homogeneous population in terms of smoking
habits, which excludes that risk factor as a possible bias,
as has been reported [28,30].Conclusion
Our results suggest that long-term treatment with
aspirin in patients with NMIBC might play a role on
reducing the risk of bladder tumor recurrence, average
number of resections, and number of lesions in recur-
rence in patients who underwent TURB for NMIBC. In
contrast, data from statins and combination treatment
groups showed increased recurrence rates and progression
of the disease. Based on this retrospective review, we
planned a prospective, long-term randomized controlled
study to conclusively determine the effects of these
two categories of drugs on the recurrence rate and the
progression of BC.Abbreviations
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